EFFECTS OF DIDEOXYINOSINE AND DIDEOXYCYTIDINE ON THE INTRACELLULAR PHOSPHORYLATION OF ZIDOVUDINE IN HUMAN MONONUCLEAR-CELLS

被引:25
作者
VEAL, GJ [1 ]
WILD, MJ [1 ]
BARRY, MG [1 ]
BACK, DJ [1 ]
机构
[1] UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND
关键词
ZIDOVUDINE; INTRACELLULAR PHOSPHORYLATION; DRUG INTERACTIONS;
D O I
10.1111/j.1365-2125.1994.tb04361.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Zidovudine (3'-azido-2',3'-dideoxythymidine; AZT; ZDV) is a dideoxynucleoside analogue active against human immunodeficiency virus (HIV). We are currently investigating the intracellular metabolism of ZDV to its putative active triphosphate form (ZDV triphosphate) in peripheral blood mononuclear cells and a lymphoblastoid cell line (h1A2v2). 2 Optimal conditions for intracellular phosphate formation in peripheral blood mononuclear cells occurred following a 72 h preincubation with the mitogen phytohaemagglutinin at a concentration of 10 mu g ml(-1). ZDV was metabolized predominantly to the monophosphate with smaller amounts of the di- and triphosphate anabolites. There was considerable inter- and intraindividual variability in phosphate formation in peripheral blood mononuclear cells. A similar pattern of phosphorylation was seen with the h1A2v2 lymphoblastoid cell line with ZDV monophosphate being the major metabolite. 3 With increasing interest in combination nucleoside analogue therapy in HIV-positive patients it is important to know if an interaction occurs at the level of phosphorylation. Neither dideoxyinosine (ddI) or dideoxycytidine (ddC) significantly reduced the intracellular phosphorylation of ZDV in either peripheral blood mononuclear cells or h1A2v2 cells. In contrast thymidine always gave marked inhibition (e.g. at 2.0 mu M, 89% inhibition of total phosphate formation in peripheral blood mononuclear cells and 79% in h1A2v2 cells). It is, therefore, unlikely that in vivo either ddI or ddC will perturb ZDV phosphorylation.
引用
收藏
页码:323 / 328
页数:6
相关论文
共 38 条
[1]   INITIAL STUDIES ON THE CELLULAR PHARMACOLOGY OF 2',3'-DIDEOXYINOSINE, AN INHIBITOR OF HIV INFECTIVITY [J].
AHLUWALIA, G ;
COONEY, DA ;
MITSUYA, H ;
FRIDLAND, A ;
FLORA, KP ;
HAO, Z ;
DALAL, M ;
BRODER, S ;
JOHNS, DG .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (22) :3797-3800
[2]  
ARNER ESJ, 1992, J BIOL CHEM, V267, P10968
[3]   ZIDOVUDINE PHARMACOKINETICS IN ZIDOVUDINE-INDUCED BONE-MARROW TOXICITY [J].
BARRY, M ;
HOWE, JL ;
BACK, DJ ;
SWART, AM ;
BRECKENRIDGE, AM ;
WELLER, IVD ;
BEECHING, N ;
NYE, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (01) :7-12
[4]  
BARRY M, 1994, BR J CLIN PHARM, V37
[5]  
BLACKLEY RL, 1990, MOL PHARMACOL, V37, P328
[6]  
BRODER S, 1990, AM J MED S5B, V88, P25
[7]   A PILOT-STUDY OF LOW-DOSE ZIDOVUDINE IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
COLLIER, AC ;
BOZZETTE, S ;
COOMBS, RW ;
CAUSEY, DM ;
SCHOENFELD, DA ;
SPECTOR, SA ;
PETTINELLI, CB ;
DAVIES, G ;
RICHMAN, DD ;
LEEDOM, JM ;
KIDD, P ;
COREY, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1015-1021
[8]   ZIDOVUDINE IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION AND CD4+ CELL COUNTS GREATER-THAN 400 PER CUBIC MILLIMETER [J].
COOPER, DA ;
GATELL, JM ;
KROON, S ;
CLUMECK, N ;
MILLARD, J ;
GOEBEL, FD ;
BRUUN, JN ;
STINGL, G ;
MELVILLE, RL ;
GONZALEZLAHOZ, J ;
STEVENS, JW ;
FIDDIAN, AP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :297-303
[9]   ASSAY FOR GENE MUTATION IN A HUMAN LYMPHOBLAST LINE, AHH-1, COMPETENT FOR XENOBIOTIC METABOLISM [J].
CRESPI, CL ;
THILLY, WG .
MUTATION RESEARCH, 1984, 128 (02) :221-230
[10]   THE SAFETY AND EFFICACY OF ZIDOVUDINE (AZT) IN THE TREATMENT OF SUBJECTS WITH MILDLY SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV) INFECTION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
HANSEN, N ;
COLLIER, AC ;
CAREY, JT ;
PARA, MF ;
HARDY, WD ;
DOLIN, R ;
POWDERLY, WG ;
ALLAN, JD ;
WONG, B ;
MERIGAN, TC ;
MCAULIFFE, VJ ;
HYSLOP, NE ;
RHAME, FS ;
BALFOUR, HH ;
SPECTOR, SA ;
VOLBERDING, P ;
PETTINELLI, C ;
ANDERSON, J .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (10) :727-737